Equities

Control Bionics Ltd

CBL:ASX

Control Bionics Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.066
  • Today's Change0.00 / 0.00%
  • Shares traded612.00
  • 1 Year change+32.00%
  • Beta0.8091
Data delayed at least 20 minutes, as of Nov 15 2024 00:42 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as motor neuron disease (MND) and amyotrophic lateral sclerosis (ALS). The Company’s products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. Its core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography (EMG) output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. It is also commercializing its advancement in its technology, the NeuroStrip.

  • Revenue in AUD (TTM)5.97m
  • Net income in AUD-5.91m
  • Incorporated2005
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Memphasys Ltd60.00k-4.44m8.82m24.00--1.01--146.92-0.004-0.0040.000050.0050.00440.3952-----32.78-19.51-54.58-25.222.67---7,403.38-12,238.500.2767-13.900.4104--290.37---30.55---21.39--
Uscom Ltd3.77m-2.07m11.27m11.00--3.60--2.99-0.0118-0.01180.02140.01250.73160.887411.28---40.23-30.60-53.05-36.9783.8086.20-54.99-53.502.54-17.760.2443--38.730.997719.92---12.44--
Atomo Diagnostics Ltd4.24m-6.85m13.42m----1.33--3.17-0.0108-0.01080.00670.01580.30441.253.09---49.17-31.42-54.41-34.2041.4842.58-161.56-120.994.84--0.0083--66.6351.0131.23---54.38--
Control Bionics Ltd5.97m-5.91m16.34m----2.10--2.74-0.0381-0.03810.03740.03150.67322.412.98---66.73-41.07-85.40-45.9775.6268.78-99.13-92.331.40-112.620.133--2.0846.24-5.02--67.72--
Resonance Health Ltd8.80m169.31k17.47m18.00111.761.5526.171.980.00030.00030.01880.02450.5631--5.08--1.08-3.191.40-3.56----1.92-7.63----0.2527--95.1519.18121.70-33.171.63--
Singular Health Group Ltd945.75k-2.88m18.82m----12.35--19.89-0.018-0.03080.00630.00740.35368.7322.14---107.62---331.71--124.56---304.36--2.42--0.1316--112.26--42.12------
ImExHS Ltd24.68m-3.42m19.05m400.00--1.26--0.7718-0.0794-0.07940.57130.33141.1097.113.7861,692.52-15.28-22.17-20.83-29.2131.9529.75-13.85-31.201.53-4.580.0593--14.7926.48-37.97--5.61--
Lumos Diagnostics Holdings Ltd17.25m-13.32m23.86m----1.49--1.38-0.0276-0.02760.0350.02150.4264.377.02---32.88-40.29-54.62-58.0763.7749.44-77.19-151.150.6949-6.010.5314--5.6619.534.22---47.99--
Data as of Nov 15 2024. Currency figures normalised to Control Bionics Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.